Skip to Main Content

Paper Details

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Curr Diab Rep
4
2022
Author NameAffiliation
David Z I CherneyUniversity Health Network
David Z I CherneyUniversity of Toronto
David Z I CherneyInstitute of Medical Sciences, University of Toronto
David Z I CherneyUniversity of Toronto
David Z I CherneyToronto General Hospital, University Ave
  • 1 - 5

Datasets

Release 1.2